Skip to main content

Advertisement

Table 4 Observed change from baseline to week 24 by region in the placebo group

From: Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program

  Eastern Europe/Turkey (n = 259a) Western Europe/Israel (n = 254b) USA/Canada (n = 145c) South America/Mexico (n = 119d) Asia (n = 53) Australia/South Africa (n = 32e) p value for equality of variances
ADAS-Cog, mean (SD) 0.32 (6.59) 1.40 (6.24)SA 0.55 (5.72) −0.71 (5.32)WE 0.17 (5.28) 1.56 (5.89) 0.29
ADCS-CGIC, mean (SD)f 4.18 (0.95)WE 4.51 (1.03)EE,SA 4.39 (0.90)SA 3.98 (1.35)WE,US 4.30 (0.85) 4.41 (1.04) < 0.0001
ADCS-ADL23, mean (SD) −0.59 (7.59)WE −3.21 (7.68)EE −1.78 (8.45) −1.44 (7.07) −1.77 (5.71) −2.76 (8.03) 0.60
NPI, mean (SD) −1.03 (9.95) 0.45 (9.39) −0.46 (10.53) −1.39 (11.42) −0.13 (6.44) −1.73 (10.32) 0.66
MMSE, mean (SD) 0.10 (3.08)WE,US −0.79 (2.80)EE −0.77 (3.00)EE −0.34 (2.34) −0.58 (2.73) −1.22 (3.03) 0.42
  1. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive subscale, ADCS-ADL23 Alzheimer’s Disease Cooperative Study—Activities of Daily Living, 23-item version, ADCS-CGIC Alzheimer’s Disease Cooperative Study—Clinical Global Impression of Change, MMSE Mini–Mental State Examination, NPI Neuropsychiatric Inventory, SD standard deviation
  2. Pairwise comparisons: EEp < 0.05 versus Eastern Europe/Turkey; WEp < 0.05 versus Western Europe/Israel; USp < 0.05 versus USA/Canada; SAp < 0.05 versus South America/Mexico
  3. aExcept MMSE, n = 260
  4. bExcept ADCS-CGIC, n = 250
  5. cExcept ADCS-CGIC, n = 143
  6. dExcept ADCS-CGIC, n = 117
  7. eExcept ADCS-ADL23 and NPI, n = 33
  8. fMean (SD) score at week 24 is presented for ADCS-CGIC. The scale is itself a measure of change from baseline, meaning that change scores are not applicable. Scores > 4 indicate worsening